The Endocrinologist (ENDOCRINOLOGIST)

Publisher: Lippincott, Williams & Wilkins

Journal description

This journal exists to promote the transfer of new discoveries in endocrinology, diabetes, and metabolism into clinical practice. To review and set clinical standards in endocrinology and metabolism. To upgrade the practice of medicine by publishing information relevant to the practitioner in the form of invited mini-reviews, historical vignettes, book reviews, and current literature reviews all chosen for their relevance to the day-to-day practice of endocrinology.

Current impact factor: 0.12

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2012 Impact Factor 0.116
2011 Impact Factor 0.092
2010 Impact Factor 0.124
2009 Impact Factor 0.102
2008 Impact Factor 0.141
2007 Impact Factor 0.164
2006 Impact Factor 0.216
2005 Impact Factor 0.344
2004 Impact Factor 0.349
2003 Impact Factor 0.434
2002 Impact Factor 0.333
2001 Impact Factor 0.474
2000 Impact Factor 0.382
1999 Impact Factor 0.551
1998 Impact Factor 0.653
1997 Impact Factor 0.684
1996 Impact Factor 0.792

Impact factor over time

Impact factor
Year

Additional details

5-year impact 0.11
Cited half-life 9.90
Immediacy index 0.01
Eigenfactor 0.00
Article influence 0.03
Website Endocrinologist, The website
Other titles The Endocrinologist
ISSN 1051-2144
OCLC 21915299
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

Lippincott, Williams & Wilkins

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • Pre-print must be removed upon acceptance for publication
    • Post-print may be deposited in personal website or institutional repository
    • Publisher's version/PDF cannot be used
    • Must include statement that it is not the final published version
    • Published source must be acknowledged with full citation
    • Set statement to accompany deposit
    • Must link to publisher version
    • NIH authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 12 months embargo (see policy for details)
    • Wellcome Trust and HHMI authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 6 months embargo (see policy for details)
    • RCUK authors articles will be released as Creative Commons Attribution Non-Commercial No Derivatives after 6 months
    • This policy is an exception to the default policies of 'Lippincott, Williams & Wilkins'
  • Classification
    yellow

Publications in this journal


  • No preview · Article · Dec 2015 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report and discuss a case of a young woman with a massive goiter, which was attributed to a rare genetic disorder. We review the history and diagnostic tests including radiology, blood tests, and genetic results. Diagnostic tests revealed a large goiter, dilated vestibular aqueduct, mondini dysplasia, and a positive genetic test for SLC26A4 gene mutation. Although sporadic goiter and autoimmune thyroid disorders are common in the population, we suspected Pendred syndrome based on the presentation of massive goiter from dyshormonogenesis and hearing loss. The diagnosis of Pendred syndrome was confirmed by the genetic tests. The implication of the diagnosis is important for further genetic counseling.
    No preview · Article · Nov 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lipodystrophies are rare disorders. Familial partial lipodystrophy of the Dunnigan type (FPLD) is characterized by loss of subcutaneous fat from the limbs and trunk. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol. In these patients, the prevalence of polycystic ovaries and infertility is higher than in the general population. Besides infertility, clinical signs of hyperandrogenism can be of great importance for affected women. We report a case of a 32-year-old woman with FPLD. The patient suffered from severe hirsutism. Hormone serum measurements showed an elevated testosterone. After detailed consultation with the treating internist, antiandrogenic hormone therapy was initiated. The article summarizes the possibilities, problems, and results of antiandrogenic therapy in a patient with FPLD.
    No preview · Article · Nov 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-induced osteomalacia is a paraneoplastic syndrome caused by a mesenchymal tumor elaborating a hormone that induces renal-phosphate wasting. Clinical manifestations include hypophosphatemia, muscle weakness, bone pain, osteomalacia, and fractures. The debilitating disorder may be completely cured if the tumor is surgically removed, but its localization can be clinically challenging. In this case report, we discuss the clinical presentation, biochemical, radiologic, and microscopic data in a 58-year-old man with tumor-induced osteomalacia in whom tumor localization was successful via whole-body sestamibi scanning.
    No preview · Article · Nov 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of hepatic and renal function on the development of the metabolic syndrome is not well studied in obese, middle-aged, and elderly people. We enrolled 117 consecutive overweight or obese patients and measured their aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, and serum uric acid levels. In all, 82 patients (70%) had the metabolic syndrome. Patients with the metabolic syndrome had considerably increased serum uric acid, alanine aminotransferase, and gamma- glutamyltransferase levels. Moreover, serum uric acid, alanine aminotransferase, and gamma-glutamyltransferase levels increased as the number of components of the metabolic syndrome increased. These biochemical markers could help identify patients with the metabolic syndrome who are at increased risk for future cardiovascular events. The above-mentioned markers seem to have a diagnostic ability in classifying obese people with metabolic syndrome. Whether by lowering serum uric acid and gamma-glutamyltransferase levels with the use of drugs or simply by avoiding alcohol consumption could we ameliorate cardiovascular risk among patients with the metabolic syndrome, remains to be elucidated.
    No preview · Article · Nov 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 73-year-old woman with an 11-year history of type 2 diabetes mellitus and hypertension was admitted to hospital because of acute confusion. Laboratory analysis showed severe hyponatremia with a serum sodium concentration of 109 mEq/L. No edema was found in her extremities. Neurologic examination revealed no abnormalities. She had been taking pioglitazone for 4 months. Sodium level was normal before the start of pioglitazone. Her blood pressure was 150/90 mm Hg. Serum and urine osmolalities were 245 and 613 mOsm/kg, respectively. Thyroid function tests, plasma corticotropin, and serum cortisol concentrations were normal. Clinical history and laboratory findings suggested that the cause of the severe hyponatremia was the syndrome of inappropriate antidiuretic hormone secretion caused by pioglitazone therapy. After withdrawal of pioglitazone, she was treated with infusion of hypertonic saline (3% sodium chloride, 300 mL/24 h) for 3 days. The patient's sodium concentration increased gradually and the clinical situation improved rapidly. Her serum sodium returned to nearly normal ranges within 1 week and she was discharged.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gonadotropin-releasing hormone (GnRH) agonists have been used for more than 2 decades in the treatment of prostate cancer. 1 There are few case reports of pituitary apoplexy occurring after administration of this class of drug. All of these case reports describe patients with an unknown pituitary adenoma.(2-6) We describe a case of a patient who developed pituitary apoplexy after receiving leuprolide but had no evidence of a pituitary tumor. Clinicians who manage this subset of patients should be aware of this rare complication.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: An adrenal incidentaloma is an adrenal mass, generally 1 cm or more in diameter that is discovered serendipitously during a radiologic examination performed for indication other than evaluation for adrenal disease. With the increasing use of ultrasonography, computerized tomography, and magnetic resonance tomography, an adrenal mass may be identified more frequently. Most adrenal incidentalomas are nonfunctioning adenomas. Metastatic cancer should be considered in patients with known malignancy and having an adrenal mass with suspicious imaging characteristics. Although adrenal metastases are frequently bilateral and greater than 3 cm in size, they may be unilateral and small. A fine-needle biopsy of an adrenal mass may be indicated for diagnosis in such cases. Adrenal carcinoma presenting as an incidental adrenal mass is exceedingly rare. Metastatic tumors in people with no known malignancy is considerably more common. The following report illustrates 1 such case in a 57-year-old man with no prior malignancy, presenting with hemoptysis due to a cavitary lesion in his right lung. A large, right adrenal mass with suspicious imaging characteristics was incidentally noted. Fine-needle biopsy of the adrenal mass proved to squamous cell carcinoma, most likely of the lung. This is a rare case of lung carcinoma (hitherto unknown) presenting with an adrenal mass, where final diagnosis was made by adrenal biopsy.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 36-year-old man was admitted because of muscle weakness. He had a history of hypertension since the age of 20 years. He worked in a hot and humid environment, and his symptoms first appeared at work. He was diagnosed with hypokalemic myopathy. He exhibited a right-hand grasping power of 0 kg and walking difficulties. Further examination revealed a right adrenal gland adenoma and led to a diagnosis of primary aldosteronism (PA). Because PA can now be screened by measuring aldosterone and renin in plasma, PA with extreme myopathy, like the present case is very rare. The causes of the myopathy were considered to be excessive sodium intake and dehydration.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: An abstract is unavailable. This article is available as HTML full text and PDF.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the contribution of ultrasonography and frozen-section analysis (FS) in the prediction of malignancy in thyroid nodules with suspicious papillary thyroid carcinoma (PTC) cytology. Methods and Results: The sample consisted of 89 patients with thyroid nodules diagnosed as suspicious for PTC by fine-needle aspiration cytology. Histology revealed malignancy in 69 of 89 patients (77.5%). Malignancy was observed in 55 of 58 nodules (94.8%) with suspicious ultrasonographic findings versus 14 of 31 (45.1%) without suspicious characteristics (P < 0.05). In 69 patients, FS revealed malignancy. Of them, 66 (95.6%) were found to be true carcinoma. In 17 of 20 patients (85%) with FS showing no malignancy, the nodule was confirmed to be benign. Conclusion: Total thyroidectomy is indicated when a thyroid nodule with suspicious PTC cytology exhibits suspicious ultrasonographic characteristics or when FS reveals malignancy. Otherwise, lobectomy should be the initial procedure in cases of nonsuspicious ultrasonographic findings and absence of malignancy upon FS.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the light of the contemporary definition of Turner syndrome (TS), not all cases of 45,X/46,XX mosaicism should be considered as this syndrome. This report describes 2 mothers with 45,X/46,XX karyotype and their offspring. In one family, a mother and 2 daughters had 45,X/46,XX mosaicism. In the second one, a mother with a mosaic karyotype delivered 2 children, 1 healthy and 1 with Xp deletion, 46,Xdel(X)(p11.2). In both families, the daughters were initially diagnosed as TS, whereas mosaicism in their mothers was confirmed during further analysis. All 3 daughters with chromosomal aberrations had somatic and/or visceral TS stigmata, menstrual cycle disturbances and 2 of them were short in stature. However, the clinical presentation differs substantially between the mothers and their offspring as well as between siblings of the same mother. We also observed that a similar karyotype may result in a dissimilar phenotype, even in 1 family. This report shows that determining the diagnosis of TS might be a complicated task, especially in patients with low 45,X/46,XX mosaicism. It also indicates that there is a need for genetic counseling for mothers of daughters with TS.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the effects of hypothyroidism or hyperthyroidism on weight have clearly been demonstrated, data regarding the effects of relatively minor defects in thyroid function are limited. In the present study, the relationship between body mass index (BMI) and alterations in thyroid function within the normal range was investigated in obese patients. Three hundred fifty-seven euthyroid, obese patients (309 female and 48 male; mean age, 42 years) were included in the study. The patients were divided into 2 groups based on a BMI threshold value of 40 kg/m2. Thyroid function, BMI, and the epidemiologic characteristics of the patients were retrospectively evaluated. No statistically significant difference was detected between the groups with respect to gender, place of birth, place of residence, smoking habits, and family history. Severely obese patients with a BMI ≥40 kg/m2 were older and had a lower serum-free thyroxine level (fT4) than obese patients with a BMI <40 kg/m2 (P < 0.01). In patients with normal thyroid function, a negative correlation between fT4 and BMI existed. No statistically significant association was detected between BMI and epidemiologic characteristics in euthyroid, obese patients.
    No preview · Article · Oct 2010 · The Endocrinologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fenofibrate, a fibric acid derivative, is frequently used to treat diabetic dyslipidemia and hypertriglyceridemia alone or in combination with statins. Rhabdomyolysis is a syndrome that results from striated muscle necrosis and release of its contents into the systemic circulation and extracellular fluid. Fenofibrate-induced rhabdomyolysis is a rare clinical condition if there is not a predisposing factor such as diabetes mellitus, hypothyroidism, and renal insufficiency. In this study, we present a case of a patient who developed rhabdomyolysis after micronized fenofibrate use without known predisposing factor.
    No preview · Article · Oct 2010 · The Endocrinologist